Thomas Richie

Thomas Richie

Auto-generated profile, based on publicly available information

Thomas Richie

Sanaria Inc., Rockville, USA

Research Focus & Metrics

Academic Career Length

49Years (1978-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2013 in Science
Verified
Journal Article
Open access
PDF file
RSRobert Seder
Robert Seder
LCLee-Jah Chang
Lee-Jah Chang
MEMary E. Enama
Mary E. Enama
KZKathryn L. Zephir
Kathryn L. Zephir
USUzma N. Sarwar
Uzma N. Sarwar
SHStephen L. Hoffman
Stephen L. Hoffman
Malaria Sporozoite Vaccine: Each year, hundreds of millions of people are infected with Plasmodium falciparum , the mosquito-borne parasite that causes malaria. A preventative vaccine is greatly needed. Seder et al. (p. 1359 , published online 8 August; see the Perspective by Good ) now report the results from a phase I clinical trial where subjects were immunized intravenously with a whole, attenuated sporozoite vaccine. Three of 9 subjects who received four doses and zero of 6 subjects who received five doses of the vaccine went on to develop malaria after controlled malaria infection. Both antibody titers and cellular immune responses correlated positively with the dose of vaccine received, suggesting that both arms of the adaptive immune response may have participated in the observed protection.

15 April 2002 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
SHStephen L. Hoffman
Stephen L. Hoffman
LGLucy M. L. Goh
Lucy M. L. Goh
TLThomas C. Luke
Thomas C. Luke
ISImogene Schneider
Imogene Schneider
TLThong P. Le
Thong P. Le
TRThomas L. Richie
Thomas L. Richie
During 1989–1999, 11 volunteers were immunized by the bites of 1001–2927 irradiated mosquitoes harboring infectious sporozoites of Plasmodium falcipa

28 October 2011 in Science
Verified
Journal Article
Open access
PDF file
JEJ. E. Epstein
J. E. Epstein
KTK. Tewari
K. Tewari
KLK. E. Lyke
K. E. Lyke
BSB. K. L. Sim
B. K. L. Sim
PBP. F. Billingsley
P. F. Billingsley
SHS. L. Hoffman
S. L. Hoffman
Our goal is to develop a vaccine that sustainably prevents Plasmodium falciparum (Pf) malaria in ≥80% of recipients. Pf sporozoites (PfSPZ) administered by mosquito bites are the only immunogens shown to induce such protection in humans. Such protection is thought to be mediated by CD8+ T cells in the liver that secrete interferon-γ (IFN-γ). We report that purified irradiated PfSPZ administered to 80 volunteers by needle inoculation in the skin was safe, but suboptimally immunogenic and protective. Animal studies demonstrated that intravenous immunization was critical for inducing a high frequency of PfSPZ-specific CD8+, IFN-γ–producing T cells in the liver (nonhuman primates, mice) and conferring protection (mice). Our results suggest that intravenous administration of this vaccine will lead to the prevention of infection with Pf malaria.

1 January 2010 in Human Vaccines
Verified
Journal Article
Open access
SHStephen L. Hoffman
Stephen L. Hoffman
PBPeter F. Billingsley
Peter F. Billingsley
EJEric James
Eric James
ARAdam Richman
Adam Richman
MLMark Loyevsky
Mark Loyevsky
BSB. Kim Lee Sim
B. Kim Lee Sim
(2010). Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Human Vaccines: Vol. 6, No. 1, pp. 97-106.

7 February 2002 in Nature
Verified
Journal Article
Closed access
TRThomas L. Richie
Thomas L. Richie
ASAllan Saul
Allan Saul

17 May 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RDRebecca Danner
Rebecca Danner
SCSnehal N. Chaudhari
Snehal N. Chaudhari
JRJohn Rosenberger
John Rosenberger
JSJacqueline Surls
Jacqueline Surls
TRThomas L. Richie
Thomas L. Richie
SCSofia Casares
Sofia Casares
Humanized mice able to reconstitute a surrogate human immune system (HIS) can be used for studies on human immunology and may provide a predictive preclinical model for human vaccines prior to clinical trials. However, current humanized mouse models show sub-optimal human T cell reconstitution and limited ability to support immunoglobulin class switching by human B cells. This limitation has been attributed to the lack of expression of Human Leukocyte Antigens (HLA) molecules in mouse lymphoid organs. Recently, humanized mice expressing HLA class I molecules have been generated but showed little improvement in human T cell reconstitution and function of T and B cells. We have generated NOD.Rag1KO.IL2RγcKO mice expressing HLA class II (HLA-DR4) molecules under the I-Ed promoter that were infused as adults with HLA-DR-matched human hematopoietic stem cells (HSC). Littermates lacking expression of HLA-DR4 molecules were used as control. HSC-infused HLA-DR4.NOD.Rag1KO.IL-2RγcKO mice developed a very high reconstitution rate (>90%) with long-lived and functional human T and B cells. Unlike previous humanized mouse models reported in the literature and our control mice, the HLA-DR4 expressing mice reconstituted serum levels (natural antibodies) of human IgM, IgG (all four subclasses), IgA, and IgE comparable to humans, and elicited high titers of specific human IgG antibodies upon tetanus toxoid vaccination. Our study demonstrates the critical role of HLA class II molecules for development of functional human T cells able to support immunoglobulin class switching and efficiently respond to vaccination.